Contact
searchSearch
HMP Global
Login

Colorectal Cancer Excellence Forum

Colorectal Cancer
Excellence Forum

Davide Ciardiello, MD
Videos
HER2 Alterations Predict Inferior Survival With Anti-EGFR Therapy in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
03/11/2026
Davide Ciardiello, MD, discusses exploratory findings from the CAPRI-2 GOIM trial assessing the clinical impact of HER2 alterations in patients with RAS/BRAFV600 wild-type, microsatellite-stable metastatic colorectal cancer receiving...
Davide Ciardiello, MD, discusses exploratory findings from the CAPRI-2 GOIM trial assessing the clinical impact of HER2 alterations in patients with RAS/BRAFV600 wild-type, microsatellite-stable metastatic colorectal cancer receiving...
Davide Ciardiello, MD, discusses...
03/11/2026
Oncology
Veronica Conca, MD
Videos
mFOLFOXIRI Plus Panitumumab Improves Overall Survival in RAS/BRAF Wild-Type mCRC
03/10/2026
Veronica Conca, MD, discusses final results from the phase 3 TRIPLETE study comparing first-line mFOLFOXIRI plus panitumumab versus mFOLFOX plus panitumumab in RAS/BRAF wild-type metastatic colorectal cancer.
Veronica Conca, MD, discusses final results from the phase 3 TRIPLETE study comparing first-line mFOLFOXIRI plus panitumumab versus mFOLFOX plus panitumumab in RAS/BRAF wild-type metastatic colorectal cancer.
Veronica Conca, MD, discusses...
03/10/2026
Oncology
Campbell Roxburgh, MD
Videos
Short-Course Radiotherapy Shows Immunologic Advantages in Locally Advanced Rectal Cancer
02/10/2026
Campbell Roxburgh, MD
Campbell Roxburgh, MD, discusses findings from a serial sampling study evaluating immune effects of neoadjuvant radiotherapy regimens in patients with locally advanced rectal cancer.
Campbell Roxburgh, MD, discusses findings from a serial sampling study evaluating immune effects of neoadjuvant radiotherapy regimens in patients with locally advanced rectal cancer.
Campbell Roxburgh, MD, discusses...
02/10/2026
Oncology
Stefania Napolitano, MD, PhD
Videos
ctDNA-Guided Selection Optimizes Anti-EGFR Rechallenge in Metastatic Colorectal Cancer
01/29/2026
Stefania Napolitano, MD, PhD
Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD,...
01/29/2026
Oncology
Stefania Napolitano, MD, PhD
Videos
Anti-EGFR Rechallenge in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/29/2026
Stefania Napolitano, MD, PhD
Stefania Napolitano, MD, PhD, discusses background and methods from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD, discusses background and methods from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD,...
01/29/2026
Oncology
Scott Kopetz, MD, PhD
Videos
Encorafenib Plus Cetuximab and FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
01/16/2026
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, discusses results from Cohort 3 of the phase 3 BREAKWATER study evaluating encorafenib plus cetuximab with FOLFIRI versus control therapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
Scott Kopetz, MD, PhD, discusses results from Cohort 3 of the phase 3 BREAKWATER study evaluating encorafenib plus cetuximab with FOLFIRI versus control therapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
Scott Kopetz, MD, PhD, discusses...
01/16/2026
Oncology
Scott Kopetz, MD, PhD
Videos
Encorafenib Plus Cetuximab and mFOLFOX6 for Patients With BRAF V600E-Mutated Metastatic Colorectal Cancer
09/10/2025
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, discusses results from the BREAKWATER study which demonstrated that encorafenib plus cetuximab and mFOLFOX6 improved survival outcomes compared to standard of care among previously untreated patients with BRAF...
Scott Kopetz, MD, PhD, discusses results from the BREAKWATER study which demonstrated that encorafenib plus cetuximab and mFOLFOX6 improved survival outcomes compared to standard of care among previously untreated patients with BRAF...
Scott Kopetz, MD, PhD, discusses...
09/10/2025
Oncology
John Strickler, MD
Videos
Addition of FOLFIRI to Sotorsaib and Panitumumab Demonstrates Long-Term Efficacy, Safety Among Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
08/21/2025
John Strickler, MD
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses...
08/21/2025
Oncology
Arvind Dasari, MD
Conference Coverage
Use of ctDNA Monitoring During Colorectal Cancer Treatment to Identify Patients Eligible for Curative-Intent Metastasis-Directed Therapy
08/05/2025
Arvind Dasari, MD
Arvind Dasari, MD, discusses study results which assessed the clinical utility of adding ctDNA monitoring to standard colorectal cancer treatment to better identify patients eligible for curative-intent metastasis-directed therapy.
Arvind Dasari, MD, discusses study results which assessed the clinical utility of adding ctDNA monitoring to standard colorectal cancer treatment to better identify patients eligible for curative-intent metastasis-directed therapy.
Arvind Dasari, MD, discusses...
08/05/2025
Oncology
Eric Christenson, MD
Videos
Nivolumab Plus Relatlimab For Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer
08/04/2025
Eric Christenson, MD
Eric Christenson, MD, discusses results from a phase 2 clinical trial highlighting the impact of combining nivolumab with relatlimab on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch...
Eric Christenson, MD, discusses results from a phase 2 clinical trial highlighting the impact of combining nivolumab with relatlimab on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch...
Eric Christenson, MD, discusses...
08/04/2025
Oncology

Recent News

FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use